[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369826-105":59,"doc-detail-369826-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteogenomic-and-observational-evidence-implicate-angptl4-as-a-potential-therapeutic-target-for-colorectal-cancer-prevention","Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention","","Background: The role of lipid-perturbing medications in cancer risk is unclear. Methods: The study used cis-Mendelian randomization and colocalization to assess five lipid-perturbing drug targets (ANGPTL3, ANGPTL4, APOC3, CETP, and PCSK9) for risk of five cancers: breast, colorectal, head and neck, ovarian, and prostate. Findings were triangulated using pre-diagnostic protein measures in EPIC and the UK Biobank. Mechanistic insight focused on ANGPTL4 p.E40K loss-of-function variant effects on gene expression in normal colon tissue.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteogenomic-and-observational-evidence-implicate-angptl4-as-a-potential-therapeutic-target-for-colorectal-cancer-prevention/369826/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteogenomic-and-observational-evidence-implicate-angptl4-as-a-potential-therapeutic-target-for-colorectal-cancer-prevention/369826.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about cancer risk?","Question",{"text":112,"@type":113},"It evaluates whether lipid-perturbing medications are involved in cancer risk and specifically examines ANGPTL4 as a potential therapeutic target for colorectal cancer prevention.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which methods are used to assess the drug targets and cancer risks?",{"text":117,"@type":113},"The study applies cis-Mendelian randomization and colocalization, and triangulates results with pre-diagnostic protein measures from EPIC and the UK Biobank.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanistic work is performed regarding ANGPTL4?",{"text":121,"@type":113},"It examines how the ANGPTL4 p.E40K loss-of-function variant influences differential gene expression in normal colon tissue.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369826,1790712978,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","JNCI: Journal of the National Cancer Institute, 2025, 117(9), 1836–1847  \n[https://doi.org/10.1093/jnci/djaf137](https://doi.org/10.1093/jnci/djaf137)  \nAdvance Access Publication Date: June 13, 2025  \nArticle  \nProteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention  \nJames Yarmolinsky , PhD􀀃 ,1 , Matthew A. Lee , PhD2, Evelyn Lau , PhD3, Ferran Moratalla-Navarro , PhD4, 5,6, 7, Emma E. Vincent , PhD8,9, 10, Ruifang Li-Gao , PhD11, Patrick C.N. Rensen , PhD12, 13, Ko Willems van Dijk , PhD12, 13, 14, Kostas K. Tsilidis , PhD1, 15, Apiwat Sangphukieo , PhD16, Elmira Ebrahimi , MSc16, Jochen Hampe , MD, PhD17,  \nLoïc Le Marchand , MD, PhD18, Franzel J.B. van Duijnhoven , PhD19, Kala Visvanathan , MD20, Michael O. Woods , PhD21,  \nMarcela Guevara , MD, PhD22, 23, 24, Sabina Sieri , PhD25, Giovanna Masala , MD26, Keren Papier , PhD27, ShamaVirani , PhD16, Tom Dudding , PhD28, Abbas Dehghan , MD, PhD1,29, Alexander G. Smith , PhD1, Dennis Wang , PhD3,30, Victor Moreno , PhD4, 5,6, 7, Marc J. Gunter, PhD1, 2, Ioanna Tzoulaki , PhD1, 29,31 1Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom  \n2Nutrition and Metabolism Branch (NME), International Agency for Research on Cancer, Lyon, France  \n3Institute for Human Development and Potential, Agency for Science, Technology and Research (A􀀃 STAR), Singapore, Republic of Singapore  \n4Unit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain  \n5ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain 6Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain  \n7Department of Clinical Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), Faculty of Medicine, University of Barcelona, Barcelona, Spain  \n8MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom  \n9Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom 10Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom 11Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands  \n12Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands 13Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands 14Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands  \n15Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece 16Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France  \n17Department of Medicine I, University Hospital Dresden, Technische Universit€at Dresden (TU Dresden), Dresden, Germany 18Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, United States  \n19Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands 20Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States 21Discipline of Genetics, Memorial University of Newfoundland, St John's, NL, Canada  \n22Instituto de Salud Pblica y Laboral de Navarra, Pamplona, Spain  \n23Centro de Investigacin Biomdica en Red de Epidemiologa y Salud Pblica (CIBERESP), Madrid, Spain 24Navarra Institute for Health Research (IdiSNA), Pamplona, Spain  \n25Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy  \n26Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy 27Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, Uni","cbCaiaNPlybyRBlB","https://ap.wps.com/l/cbCaiaNPlybyRBlB","pdf",1209856,12,"English","# Abstract\n## Background\n## Methods\n## Mechanistic evaluation","[{\"question\":\"What question does the study address about cancer risk?\",\"answer\":\"It evaluates whether lipid-perturbing medications are involved in cancer risk and specifically examines ANGPTL4 as a potential therapeutic target for colorectal cancer prevention.\"},{\"question\":\"Which methods are used to assess the drug targets and cancer risks?\",\"answer\":\"The study applies cis-Mendelian randomization and colocalization, and triangulates results with pre-diagnostic protein measures from EPIC and the UK Biobank.\"},{\"question\":\"What mechanistic work is performed regarding ANGPTL4?\",\"answer\":\"It examines how the ANGPTL4 p.E40K loss-of-function variant influences differential gene expression in normal colon tissue.\"}]","Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention | PDF",1790184767,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a7cbeee3d91096f79a7c4a16366c214.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa933b81877c52483565bf9dd3467e82.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d6373e42f3a8381b83bfaef95fef46a.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4eae880b714872fab526eacc4148121.webp",980,1287]